Literature DB >> 28586124

Small heterodimer partner deletion prevents hepatic steatosis and when combined with farnesoid X receptor loss protects against type 2 diabetes in mice.

Oludemilade Akinrotimi1, Ryan Riessen1, Philip VanDuyne1, Jung Eun Park2, Yoon Kwang Lee2, Lee-Jun Wong3, Ann M Zavacki4, Kristina Schoonjans5, Sayeepriyadarshini Anakk1.   

Abstract

Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP) are important regulators of bile acid, lipid, and glucose homeostasis. Here, we show that global Fxr -/- Shp-/- double knockout (DKO) mice are refractory to weight gain, glucose intolerance, and hepatic steatosis when challenged with high-fat diet. DKO mice display an inherently increased capacity to burn fat and suppress de novo hepatic lipid synthesis. Moreover, DKO mice were also very active and that correlated well with the observed increase in phosphoenolpyruvate carboxykinase expression, type IA fibers, and mitochondrial function in skeletal muscle. Mechanistically, we demonstrate that liver-specific Shp deletion protects against fatty liver development by suppressing expression of peroxisome proliferator-activated receptor gamma 2 and lipid-droplet protein fat-specific protein 27 beta.
CONCLUSION: These data suggest that Fxr and Shp inactivation may be beneficial to combat diet-induced obesity and uncover that hepatic SHP is necessary to promote fatty liver disease. (Hepatology 2017;66:1854-1865).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28586124      PMCID: PMC5696047          DOI: 10.1002/hep.29305

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

1.  Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice.

Authors:  Tiangang Li; Erika Owsley; Michelle Matozel; Peter Hsu; Colleen M Novak; John Y L Chiang
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

2.  Transcriptional activation of Fsp27 by the liver-enriched transcription factor CREBH promotes lipid droplet growth and hepatic steatosis.

Authors:  Xu Xu; Jong-Gil Park; Jae-Seon So; Ann-Hwee Lee
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

3.  Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification.

Authors:  Clinton R Bruce; Camilla Brolin; Nigel Turner; Mark E Cleasby; Feike R van der Leij; Gregory J Cooney; Edward W Kraegen
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-12-19       Impact factor: 4.310

4.  The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes.

Authors:  Li Wang; Jun Liu; Pradip Saha; Jiansheng Huang; Lawrence Chan; Bruce Spiegelman; David D Moore
Journal:  Cell Metab       Date:  2005-10       Impact factor: 27.287

5.  Contribution of variants in the small heterodimer partner gene to birthweight, adiposity, and insulin levels: mutational analysis and association studies in multiple populations.

Authors:  Chiao-Chien Connie Hung; I Sadaf Farooqi; Ken Ong; Jian'an Luan; Julia M Keogh; Marcus Pembrey; Giles S H Yeo; David Dunger; Nicholas J Wareham; Stephen O' Rahilly
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

6.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.

Authors:  Toshiya Tanaka; Joji Yamamoto; Satoshi Iwasaki; Hiroshi Asaba; Hiroki Hamura; Yukio Ikeda; Mitsuhiro Watanabe; Kenta Magoori; Ryoichi X Ioka; Keisuke Tachibana; Yuichiro Watanabe; Yasutoshi Uchiyama; Koichi Sumi; Haruhisa Iguchi; Sadayoshi Ito; Takefumi Doi; Takao Hamakubo; Makoto Naito; Johan Auwerx; Masashi Yanagisawa; Tatsuhiko Kodama; Juro Sakai
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

Review 7.  Nuclear receptors and the control of metabolism.

Authors:  Gordon A Francis; Elisabeth Fayard; Frédéric Picard; Johan Auwerx
Journal:  Annu Rev Physiol       Date:  2002-05-01       Impact factor: 19.318

8.  All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade.

Authors:  Seong Chul Kim; Chun-Ki Kim; David Axe; Aaron Cook; Mikang Lee; Tiangang Li; Nicole Smallwood; John Y L Chiang; James P Hardwick; David D Moore; Yoon Kwang Lee
Journal:  Hepatology       Date:  2014-03-26       Impact factor: 17.425

9.  TGR5-mediated bile acid sensing controls glucose homeostasis.

Authors:  Charles Thomas; Antimo Gioiello; Lilia Noriega; Axelle Strehle; Julien Oury; Giovanni Rizzo; Antonio Macchiarulo; Hiroyasu Yamamoto; Chikage Mataki; Mark Pruzanski; Roberto Pellicciari; Johan Auwerx; Kristina Schoonjans
Journal:  Cell Metab       Date:  2009-09       Impact factor: 27.287

10.  Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet.

Authors:  Bo Wang; Xin Rong; Mark A Duerr; Daniel J Hermanson; Per Niklas Hedde; Jinny S Wong; Thomas Q de Aguiar Vallim; Benjamin F Cravatt; Enrico Gratton; David A Ford; Peter Tontonoz
Journal:  Cell Metab       Date:  2016-01-28       Impact factor: 27.287

View more
  12 in total

1.  Beyond Farnesoid X receptor to target new therapies for NAFLD.

Authors:  Xiaoying Liu; Richard M Green
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

2.  Loss of Hepatic Small Heterodimer Partner Elevates Ileal Bile Acids and Alters Cell Cycle-related Genes in Male Mice.

Authors:  Ryan Philip Henry Shaw; Peter Kolyvas; Nathanlown Dang; Angela Hyon; Keith Bailey; Sayeepriyadarshini Anakk
Journal:  Endocrinology       Date:  2022-06-01       Impact factor: 5.051

Review 3.  Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.

Authors:  Ting-Ying Jiao; Yuan-di Ma; Xiao-Zhen Guo; Yun-Fei Ye; Cen Xie
Journal:  Acta Pharmacol Sin       Date:  2022-02-25       Impact factor: 7.169

4.  Bile acid signaling and bariatric surgery.

Authors:  Jingyan Tian; Silvia Huang; Siming Sun; Lili Ding; Eryun Zhang; Wendong Huang
Journal:  Liver Res       Date:  2017-12

5.  Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.

Authors:  Nancy Magee; An Zou; Priyanka Ghosh; Forkan Ahamed; Don Delker; Yuxia Zhang
Journal:  J Biol Chem       Date:  2019-12-12       Impact factor: 5.157

Review 6.  The long and the small collide: LncRNAs and small heterodimer partner (SHP) in liver disease.

Authors:  Jianguo Wu; Laura E Nagy; Li Wang
Journal:  Mol Cell Endocrinol       Date:  2021-03-26       Impact factor: 4.369

7.  Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases.

Authors:  Jens Tiefenbach; Lilia Magomedova; Jiabao Liu; Arkadiy A Reunov; Ricky Tsai; Neena S Eappen; Rebecca A Jockusch; Corey Nislow; Carolyn L Cummins; Henry M Krause
Journal:  Dis Model Mech       Date:  2018-08-31       Impact factor: 5.758

Review 8.  Update on FXR Biology: Promising Therapeutic Target?

Authors:  Chang Yeob Han
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

Review 9.  Sex differences feed into nuclear receptor signaling along the digestive tract.

Authors:  Angela E Dean; François Reichardt; Sayeepriyadarshini Anakk
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-07-14       Impact factor: 5.187

10.  FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption.

Authors:  Bethan L Clifford; Leslie R Sedgeman; Kevin J Williams; Pauline Morand; Angela Cheng; Kelsey E Jarrett; Alvin P Chan; Madelaine C Brearley-Sholto; Annika Wahlström; Julianne W Ashby; William Barshop; James Wohlschlegel; Anna C Calkin; Yingying Liu; Anders Thorell; Peter J Meikle; Brian G Drew; Julia J Mack; Hanns-Ulrich Marschall; Elizabeth J Tarling; Peter A Edwards; Thomas Q de Aguiar Vallim
Journal:  Cell Metab       Date:  2021-07-15       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.